Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients
Kidney Int Rep
.
2019 Aug 24;4(12):1742-1748.
doi: 10.1016/j.ekir.2019.08.010.
eCollection 2019 Dec.
Authors
Mark R Hanudel
1
,
Isidro B Salusky
1
,
Renata C Pereira
1
,
Wei Wang
2
,
Zhiying You
2
,
Kristen L Nowak
2
,
Godela M Brosnahan
2
,
Vicente E Torres
3
,
Arlene B Chapman
4
,
Ronald D Perrone
5
,
Theodore I Steinman
6
,
Kyongtae T Bae
7
,
Berenice Y Gitomer
2
,
Michel B Chonchol
2
Affiliations
1
Department of Pediatrics, Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
2
Department of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
3
Department of Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
4
Department of Medicine, Section of Nephrology, University of Chicago, Chicago, Illinois, USA.
5
Department of Medicine, Division of Nephrology, Tufts University Medical Center, Boston, Massachusetts, USA.
6
Department of Medicine and Renal Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
7
Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
PMID:
31844811
PMCID:
PMC6895647
DOI:
10.1016/j.ekir.2019.08.010
No abstract available
Grants and funding
R01 DK044863/DK/NIDDK NIH HHS/United States
UL1 TR001102/TR/NCATS NIH HHS/United States